Reducing the Risk of Recurrence in HR+/HER2- Early Breast Cancer Requires Action: Multidisciplinary Team Clinical Case Discussions

Sara Tolaney, MD, MPH
Associate Director, Susan F. Smith Center for Women’s Cancers
Director, Clinical Trials, Breast Oncology
Director, Breast Immunotherapy Clinical Research
Senior Physician
Associate Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts, United States

Elizabeth A. Mittendorf, MD, PhD, MHCM
Rob and Karen Hale Distinguished Chair in Surgical Oncology
Vice Chair for Research, Department of Surgery
Brigham and Women’s Hospital
Co-Leader, Breast Program
Dana-Farber/Harvard Cancer Center
Professor of Surgery
Harvard Medical School
Boston, Massachusetts, United States

Maria Noblet
Consultant Nurse
Portsmouth Hospitals NHS Trust
Portsmouth, United Kingdom

Frédérique Penault-Llorca, MD, PhD
Professor of Pathology
University of Clermont-Ferrand
CEO, Comprehensive Regional Cancer Institute Centre Jean Perrin
Clermont-Ferrand, France
Deputy Director, Research Team INSERTM 1240 IMoST
Head, Molecular Biology Platform Centre Jean Perrin
President, Immuno-Oncology Group, UNICANCER R & D
Paris, France